Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. by Rizzoli, R, Reginster, J, Boonen, S, Bréart, G, Diez-Perez, A, Felsenberg, D, Kaufman, J, Kanis, J, Cooper, C

“…Cutaneous effects and osteonecrosis of the jaw are of concern for denosumab (both very rare), though there are no pharmacovigilance data for this agent yet. The selective estrogen receptor modulators are associated with hot flushes, leg cramps, and, very rarely, venous thromboembolism and stroke. …”

Assessment of cardiovascular safety of anti-osteoporosis drugs by Fuggle, NR, Cooper, C, Harvey, NC, Al-Daghri, N, Brandi, M-L, Bruyere, O, Cano, A, Dennison, EM, Diez-Perez, A, Kaufman, J-M, Palacios, S, Prieto Alhambra, D, Rozenberg, S, Thomas, T, Tremollieres, F, Rizzoli, R, Kanis, JA, Reginster, JY

“…Despite findings in the early 21st century that menopausal hormone therapy was associated with coronary artery disease and venous thromboembolism (VTE), this therapy is now thought to be potentially safe (from a cardiac perspective) if started within the first 10 years of the menopause. Selective estrogen receptor modulators (SERMs) are associated with increased risk of VTE and may be related to fatal strokes (a subset of total strokes). …”

Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the... by Cooper, C, Reginster, J, Cortet, B, Diaz-Curiel, M, Lorenc, R, Kanis, J, Rizzoli, R

“…METHODS: We reviewed the efficacy and safety of calcium and vitamin D, the selective estrogen receptor modulators (SERMs), the bisphosphonates, denosumab, and strontium ranelate in studies of 3 years or longer. …”

Comparative anti-fracture effectiveness of different oral anti-osteoporosis therapies based on “real-world” data: a meta-analysis of propensity-matched cohort findings from the UK... by Khalid, S, Calderon-Larrañaga, S, Hawley, S, Ali, M, Judge, A, Arden, N, Van Staa, T, Cooper, C, Javaid, M, Prieto-Alhambra, D

“…Users of alendronate (reference group) were compared to those of (1) OBP, (2) strontium ranelate (SR), and (3) selective estrogen receptor modulators (SERMs), after matching on baseline characteristics using propensity scores. …”